MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Ofer Gonen will engage in a fireside chat with Managing Director and Senior Equity Research Analyst Swayampakula Ramakanth on September 8, 2025, at 4:30 PM ET.

Investors can access the live webcast through the company's website in the Events & Presentations section of the Investors page.

News Market Reaction – MDWD

+0.52%

+0.52% Session close to close

In the Aug 20 session, MDWD gained 0.52%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27^th Annual Global Investment Conference.

A live webcast of the event will be accessible both here and on MediWound’s website, under the Events & Presentations page of the Investors section. 

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx^®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.

For more information visit www.mediwound.com and follow us on LinkedIn.

MediWound Contacts:                                                                       

Hani Luxenburg                                                                        Daniel Ferry
Chief Financial Officer                                                             Managing Director
MediWound Ltd.                                                                        LifeSci Advisors, LLC
ir@mediwound.com                                                                 daniel@lifesciadvisors.com

Media Contact:
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com
+1-929-588-2008

FAQ

When is MediWound (MDWD) presenting at the H.C. Wainwright Conference?

MediWound will present on September 8, 2025, at 4:30 PM ET through a fireside chat with CEO Ofer Gonen.

Who will represent MediWound at the H.C. Wainwright Conference?

Ofer Gonen, MediWound's Chief Executive Officer, will represent the company in a fireside chat.

How can investors access MediWound's presentation at the H.C. Wainwright Conference?

Investors can access the live webcast through MediWound's website under the Events & Presentations page in the Investors section.

What type of company is MediWound (MDWD)?

MediWound is a global leader in next-generation enzymatic therapeutics focused on tissue repair.